


IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of claims:


Claim 1 (**currently amended**): A compound of the formula (IA), (IB), (IC), (ID), (IE) and (IF) of the generic structure of formula (I):



(I)

wherein:

i) a compound of formula (IA) is selected from:



(IA)

wherein:

R¹ is 2-(pyrazolyl-1-yl)ethyl, 3-(isoxazol-3-yloxy)propyl, 2-(thiazol-3-yloxy)ethyl, 2-(thiadiazol-3-yloxy)ethyl, 1,3-dihydroxyprop-2-yl, 1-methyl-1-hydroxymethylethyl, 1,2-dimethylpropyl, 1-methylcyclopropyl, 2,2-dimethylaziridin-1-yl, *t*-butyl, 2-morpholino-1,1-dimethylethyl, 2-pyrrolidin-1-yl-1,1-dimethylethyl,

2-methylthio-1,1-dimethylethyl, 1,3-dimethoxyprop-2-yl, 1-methoxyprop-2-yl, 1-hydroxyprop-2-yl, 1-ethoxyprop-2-yl, 1-propoxyprop-2-yl, ethoxyethyl or 2-methoxy-1,1-dimethylethyl; and


R^1 is 2-(pyrazolyl-1-yl)ethyl, 3-(isoxazol-3-yloxy)propyl, 2-(isothiazol-3-yloxy)ethyl, 2-(thiadiazol-3-yloxy)ethyl, 1,3-dihydroxyprop-2-yl, 1-methyl-1-hydroxymethylethyl, 1,1-dimethylpropyl, 1-methylecyclopropyl, *t*-butyl, 2-morpholino-1,1-dimethylethyl, 2-pyrrolidin-1-yl-1,1-dimethylethyl, 2-methylthio-1,1-dimethylethyl, 1,3-dimethoxyprop-2-yl, 1-methoxyprop-2-yl, 1-hydroxyprop-2-yl, 1-ethoxyprop-2-yl, 1-propoxyprop-2-yl, ethoxyethyl or 2-methoxy-1,1-dimethylethyl; and

R^2 is hydrogen;

or R^1 and R^2 together form 2,2-dimethylaziridin-1-yl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

ii) a compound of formula (IB) is selected from:




(IB)

wherein:

R^1 is pyrid-2-ylmethyl, 2-(2-methyl-1,2,4-triazol-5-yl)ethyl, 2-pyrid-2-ylethyl, 2-pyridazin-3-ylethyl, 2-(3,5-dimethyltriazol-4-yl)ethyl, 2-pyrid-3-ylethyl, 2-methoxyethyl, 3-(5-methylpyrazol-4-yl)propyl, 2-trifluoromethylpyrid-5-ylmethyl, 2-pyridazin-4-ylethyl, 1,1-dimethylpropyn-2-yl or 2-ethoxyethyl; and

R^1 is pyrid-2-ylmethyl, 2-(2-methyl-1,2,4-triazol-5-yl)ethyl, 2-pyrid-2-ylethyl, 2-pyridazin-3-ylethyl, 2-(3,5-dimethyltriazol-4-yl)ethyl, 2-pyrid-3-ylethyl, 2-methoxyethyl, 3-(5-methylpyrazol-4-yl)propyl, 2-trifluoromethylpyrid-5-ylmethyl,



(ID)

wherein:


R¹ is hydrogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₃alkyl, a heterocyclyl or heterocyclylC₁₋₃alkyl; wherein R¹ may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R² is hydrogen, halo or cyano;

R³ is C₂₋₆alkyl;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

v) a compound of formula (IE) is selected from:



(IE)

wherein:

R¹ is hydrogen, C₁₋₄alkyl, C₂₋₄alkenyl, C₂₋₄alkynyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₃alkyl, a heterocyclyl or heterocyclylC₁₋₃alkyl; wherein R¹ may be optionally substituted on

carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^2 is halo, cyano, C_{1-3} alkyl or C_{1-3} alkoxy;

p is 1-2; wherein the values of R^2 may be the same or different;

R^3 is hydrogen, halo or cyano;

R^4 is C_{1-4} alkyl;


~~R^5 is C_{1-6} alkyl or C_{2-6} alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;~~

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

provided that said compound is not

4-(1,2-dimethylimidazol-5-yl)-2-[2-methoxy-4-(*N*-methylsulphamoyl)-5-methylanilino] pyrimidine;

vi) a compound of formula (IF) is selected from:



(IF)

wherein:

R^1 is C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl, a heterocyclyl or heterocyclyl C_{1-3} alkyl; wherein R^1 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, dimethylamino, 2,2,2-trifluoroethoxy, phenyl or cyclopropylmethoxy;

and wherein if said heterocyclcyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^2 is halo, cyano, C_{1-3} alkyl or C_{1-3} alkoxy;

p is 0-2; wherein the values of R^2 may be the same or different;


R^3 is hydrogen, halo or cyano;

R^4 is C_{2-6} alkyl;

R^5 is C_{1-6} alkyl or C_{2-6} alkenyl; wherein R^5 may be optionally substituted on carbon by one or more methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, 2,2,2-trifluoroethoxy or cyclopropylmethoxy;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof;

vii) a compound of formula (IG) is selected from:



(IG)

wherein:

R^1 is C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{3-6} cycloalkyl, C_{3-6} cycloalkyl C_{1-3} alkyl, a heterocyclcyl or heterocyclcyl C_{1-3} alkyl; wherein R^1 may be optionally substituted on carbon by one or more methyl, ethyl, methoxy, ethoxy, propoxy, trifluoromethyl, trifluoromethoxy, dimethylamino, 2,2,2-trifluoroethoxy, phenyl or cyclopropylmethoxy; and wherein if said heterocyclcyl contains an -NH- moiety that nitrogen may be optionally substituted by one or more methyl, ethyl, acetyl, 2,2,2-trifluoroethyl or methoxyethyl;

R^2 is halo, cyano, C_{1-3} alkyl or C_{1-3} alkoxy;

~~p is 0-2; wherein the values of R² may be the same or different;~~

~~R³ is hydrogen, halo or cyano;~~

~~R⁴ is n-propyl or C₄₋₆alkyl;~~

~~or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.~~

Claim 2 (**currently amended**): The A-compound of formula (I) according to claim 1 which is a compound of formula (IA), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 3 (**currently amended**): The A-compound of formula (IA) according to claim 2 selected from:

2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

2-{4-[N-(*t*-butyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

2-{4-[N-(1-ethoxyprop-2-yl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

2-{4-[N-(1-propoxyprop-2-yl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

and

2-{4-[N-(1-methylcyclopropyl)sulphamoyl]anilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 4 (**currently amended**): The A-compound of formula (I) according to claim 1 which is a compound of formula (IB), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 5 (**currently amended**): The A-compound of formula (IB) according to claim 4 selected from:

4-(1-ethyl-2-methylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}pyrimidine;

and

~~2-{4-[N-(2-isopropoxyethyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine;~~
~~2-{4-[N-(2-propoxyethyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine;~~
~~2-{4-[N-(1,1-dimethylprop-2-ynyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine; and~~
~~2-{4-[N-(2-vinyloxyethyl)sulphamoyl]anilino}-4-(1-ethyl-2-methylimidazol-5-yl)pyrimidine;~~
 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 6 (**currently amended**): The A-compound of formula (I) according to claim 1 which is a compound of formula (IC), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 7 (**currently amended**): The A-compound of formula (IC) according to claim 6, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein
 R^1 is hydrogen, 2-methoxyethyl, methyl, or 2-ethoxyethyl, ~~2-isopropoxyethyl,~~
~~2-propoxyethyl, 2-(cyclopropylmethoxy)ethyl, 3-(*t*-butoxy)propyl,~~
~~3-[2-(2-ethoxyethoxy)ethoxy]propyl, 3-(2-methoxyethoxy)propyl, carboxymethyl,~~
~~*t*-butoxycarbonylmethyl, 2-hydroxyethyl, 2-(*N*-methylpyrrolidin-2-yl)ethyl,~~
~~*N*-ethylpyrrolidin-2-ylmethyl, 2-pyrrolidin-1-ylethyl, 2-morpholinoethyl,~~
~~3-morpholinopropyl, *N*-benzylpiperidin-4-yl, 2-piperidin-1-ylethyl, 2-dimethylaminoethyl,~~
~~2-diethylaminoethyl or methoxycarbonylmethyl; and~~
 R^2 is hydrogen or bromo;
 provided that when R^1 is 2-methoxyethyl R^2 is not hydrogen.

Claim 8 (**currently amended**): The A-compound of formula (IC) according to claim 6
 selected from:
 4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[N-(2-ethoxyethyl)sulphamoyl]anilino}
 pyrimidine; and

~~4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[N-(2-isopropoxyethyl)sulphamoyl]anilino}~~
~~pyrimidine;~~
~~4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[N-(2-propoxyethyl)sulphamoyl]anilino}~~
~~pyrimidine;~~
~~4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[N-[2-(cyclopropylmethoxy)ethyl]sulphamoyl}~~
~~anilino)pyrimidine; and~~
 4-(1-isopropyl-2-methylimidazol-5-yl)-2-{4-[N-(methyl)sulphamoyl]anilino} pyrimidine;
 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 9 (**currently amended**): The A-compound of formula (I) according to claim 1
 which is a compound of formula (ID), or a pharmaceutically acceptable salt or an *in vivo*
 hydrolysable ester thereof.

Claim 10 (**currently amended**): The A-compound of formula (ID) according to claim
 9, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein
~~R¹ is cyclopropyl, 2-methoxyethyl, 2-ethoxyethyl or tetrahydrofur-2-ylmethyl;~~
 R² is hydrogen; and
~~R³ is ethyl, propyl or isopropyl.~~

Claim 11 (**currently amended**): The A-compound of formula (ID) according to claim
 9 selected from:

4-(1-isopropylimidazol-5-yl)-2-{4-[N-(cyclopropyl)sulphamoyl]anilino}pyrimidine;
 4-(1-isopropylimidazol-5-yl)-2-{4-[N-(tetrahydrofur-2-ylmethyl)sulphamoyl]anilino}
 pyrimidine;
~~4-(1-propylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;~~
 4-(1-ethylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine; and
 4-(1-isopropylimidazol-5-yl)-2-{4-[N-(2-methoxyethyl)sulphamoyl]anilino}pyrimidine;
 or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 12 (**currently amended**): The A-compound of formula (I) according to claim 1 which is a compound of formula (IE), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 13 (**currently amended**): The A-compound of formula (IE) according to claim 12, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein
R¹ is hydrogen or 2-methoxyethyl;
R² is fluoro;
p is 1;
R³ is hydrogen; and
R⁴ is methyl.

Claim 14 (**currently amended**): The A-compound of formula (IE) according to claim 12 selected from:
2-{4-[N-(2-methoxyethyl)sulphamoyl]-2-fluoroanilino}-4-(1,2-dimethylimidazol-5-yl)pyrimidine; and
2-(4-sulphamoyl-2-fluoroanilino)-4-(1,2-dimethylimidazol-5-yl)pyrimidine;
or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 15 (**currently amended**): The A-compound of formula (I) according to claim 1 which is a compound of formula (IF), or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claim 16 (**currently amended**): The A-compound of formula (IF) according to claim 15, or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof; wherein
R¹ is methyl, 3-dimethylaminopropyl, 3-methoxypropyl, 3,3,3-trifluoropropyl, or butyl;
~~benzyl, tetrahydrofur 2-ylmethyl, 3-ethoxypropyl or 3-morpholinopropyl;~~
p is 0;
~~R³ is hydrogen or bromo;~~

R⁴ is isopropyl; and

R⁵ is methyl.

Claim 17 (**currently amended**): The A-compound of formula (IF) according to claim 15 selected from:

4-(1-isopropyl-2-methylimidazol-5-yl)-2-(4-mesylnilino)pyrimidine;

4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(tetrahydrofur-2-ylmethylsulphonyl)anilino]pyrimidine;

4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-ethoxypropylsulphonyl)anilino]pyrimidine;

4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-methoxypropylsulphonyl)anilino]pyrimidine;

and

4-(1-isopropyl-2-methylimidazol-5-yl)-2-[4-(3-*N,N*-dimethylaminopropylsulphonyl)anilino]pyrimidine;

or a pharmaceutically acceptable salt or an *in vivo* hydrolysable ester thereof.

Claims 18-20 (**cancelled**).

Claim 21 (**currently amended**): A pharmaceutical composition which comprises a compound of formula (I), or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof, according to claim 1 ~~any one of claims 1-20~~, in association with a pharmaceutically-acceptable diluent or carrier.

Claims 22-32 (**cancelled**).

Claim 33 (**previously presented**): A method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as claimed in claim 1.

Claim 34 (**cancelled**).

Claim 35 (**currently amended**): A method for treating ~~a disease or medical condition selected from cancer (solid tumours and leukaemias), fibroproliferative and differentiative disorders, psoriasis, rheumatoid arthritis, Kaposi's sarcoma, haemangioma, acute and chronic nephropathies, atheroma, atherosclerosis, arterial restenosis, autoimmune diseases, acute and chronic inflammation, bone diseases and ocular diseases with retinal vessel proliferation,~~ in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or *in vivo* hydrolysable ester thereof as claimed in claim 1.

Claims 36-38 (**cancelled**).